--- title: "Eledon Pharmaceuticals (ELDN) stock and investor profile" url: "https://aibio.space/companies/eledon-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), United States. The directory classifies it as Pharmaceuticals: Major." --- ELDN Eledon Pharmaceuticals, Inc. NASDAQ · United States # Eledon Pharmaceuticals (ELDN) news Listings · 2026-06-22 ## [Eledon holders approve raising authorized common shares to 450,000,000](https://aibio.space/news/eledon-holders-approve-raising-authorized-common-shares-450-000-000/) The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026. ## Latest Eledon Pharmaceuticals news 1. 2026-01-02 Financings [Eledon Pharmaceuticals swaps 4,203,764 shares for a pre-funded warrant with Coastlands](https://aibio.space/news/eledon-pharmaceuticals-swaps-4-203-764-shares-pre-funded-warrant/) The exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share. ## Eledon Pharmaceuticals at a glance - **Ticker**: ELDN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $88.8 million ### Related companies - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) NASDAQ: CGEM - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) NASDAQ: CNSP - [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) OTC: ZVSA - [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) NASDAQ: LFCR - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) NASDAQ: ACTU - [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX ### Also on NASDAQ - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) MDCX - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) IPSC - [908 Devices](https://aibio.space/companies/908-devices/) MASS - [INSULET CORP](https://aibio.space/companies/insulet/) PODD - [Adagene](https://aibio.space/companies/adagene/) ADAG - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA ## Eledon Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$66.3 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | [$52.0 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | | Net income (loss) | [-$45.6 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | [-$36.2 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | | Cash from operations | [-$62.3 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | [-$47.3 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | | Cash and equivalents | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349314/) | [$20.5 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | | Short-term investments | [$110.5 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349314/) | [$119.6 million](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.8 million, plus short-term investments of $82.0 million, $88.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Eledon Pharmaceuticals What is the ticker symbol of Eledon Pharmaceuticals? Eledon Pharmaceuticals, Inc. trades under the ticker ELDN on NASDAQ. Where is Eledon Pharmaceuticals listed? Eledon Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A2QL00. What is the SEC CIK of Eledon Pharmaceuticals? The SEC Central Index Key (CIK) for Eledon Pharmaceuticals, Inc. is 1404281. Its filings are on SEC EDGAR. How many shares does Eledon Pharmaceuticals have outstanding? 81,261,152 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Eledon Pharmaceuticals listed under? Our directory records Eledon Pharmaceuticals, Inc. under United States. What does Eledon Pharmaceuticals do? Our directory classifies Eledon Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Eledon Pharmaceuticals? The ISIN recorded for Eledon Pharmaceuticals, Inc. is US28617K1016. Does aibio.space cover Eledon Pharmaceuticals? aibio.space lists Eledon Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Eledon Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. Is Eledon Pharmaceuticals profitable? Eledon Pharmaceuticals, Inc. reported a net loss of $45.6 million for the fiscal year ended Dec 31, 2025, and used $62.3 million of cash in operations, per its annual report to the SEC. How much does Eledon Pharmaceuticals spend on research and development? $66.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Eledon Pharmaceuticals have? $88.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Eledon Pharmaceuticals (ELDN) stock news? Our latest story on Eledon Pharmaceuticals, dated Jun 22, 2026: "Eledon holders approve raising authorized common shares to 450,000,000". The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026. [Source](https://aibio.space/news/eledon-holders-approve-raising-authorized-common-shares-450-000-000/). What is Eledon Pharmaceuticals's latest stock offering or financing news? Our latest financing story, dated Jan 2, 2026: "Eledon Pharmaceuticals swaps 4,203,764 shares for a pre-funded warrant with Coastlands". The exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share. [Source](https://aibio.space/news/eledon-pharmaceuticals-swaps-4-203-764-shares-pre-funded-warrant/). Is Eledon Pharmaceuticals at risk of delisting? Our latest listing story, dated Jun 22, 2026: "Eledon holders approve raising authorized common shares to 450,000,000". The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026. [Source](https://aibio.space/news/eledon-holders-approve-raising-authorized-common-shares-450-000-000/). ## Investor discussion: Eledon Pharmaceuticals Members talk about Eledon Pharmaceuticals (ELDN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Eledon Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349314/eldn-20260630.htm) 2. 2026-06-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404281/000119312526277653/eldn-20260618.htm) 3. 2026-01-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404281/000119312526000968/eldn-20251230.htm) 4. 2025-08-14 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-ex99_1.htm) 5. 2025-06-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/eldn-20250610.htm) 6. 2025-04-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404281/000095017025051663/eldn-20250401.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ELDN on TradingView](https://www.tradingview.com/symbols/NASDAQ-ELDN/). ## SEC filings and registration - **SEC name**: Eledon Pharmaceuticals, Inc. - **CIK**: 1404281 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ELDN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 19800 MACARTHUR BLVD., IRVINE, CA, 92612 - **Phone**: 949-238-8090 - **Shares outstanding**: 81,261,152 as of 2026-08-10 (10-Q filed 2026-08-13) - **Former names**: Eledon Pharmaceuticals, Inc.; Novus Therapeutics, Inc.; Tokai Pharmaceuticals Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349314/eldn-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1404281/000119312526277653/eldn-20260618.htm) filed 2026-06-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1404281/000119312526221702/eldn-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-20260513.htm) filed 2026-05-13 - [S-3](https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm) filed 2026-05-01 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1404281/000119312526197732/eldn-20260430.htm) filed 2026-04-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116164/eldn-20251231.htm) filed 2026-03-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001404281), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Eledon Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ELDN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Eledon Pharmaceuticals, Inc. - **Ticker**: ELDN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US28617K1016 - **Other listed symbols**: LSX:A2QL00 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ELDN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/eledon-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eledon Pharmaceuticals (ELDN) stock and investor profile", 2026-10-31, https://aibio.space/companies/eledon-pharmaceuticals/